<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Management of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> with IV unfractionated <z:chebi fb="5" ids="28304">heparin</z:chebi> is subject to debate </plain></SENT>
<SENT sid="1" pm="."><plain>The authors evaluated patient-related and institutional factors influencing its use in 42 hospitals </plain></SENT>
<SENT sid="2" pm="."><plain>Cardioembolic <z:hpo ids='HP_0001297'>stroke</z:hpo> type, <z:hpo ids='HP_0100546'>carotid stenosis</z:hpo>, <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>, and treatment in <z:hpo ids='HP_0001297'>stroke</z:hpo> units or intensive care units significantly increased the probability of use </plain></SENT>
<SENT sid="3" pm="."><plain>However, there are large unexplained variations in IV <z:chebi fb="5" ids="28304">heparin</z:chebi> use among hospitals </plain></SENT>
</text></document>